schliessen

Filtern

 

Bibliotheken

Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study

Aims/hypothesis We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. Methods Non-diabetic offspring ( n  = 874; mean age 40 ± 10.4 years; BMI 26.6 ± 4.9 kg/m 2 ) of type 2 diabetic... Full description

Journal Title: Diabetologia 2007-12-14, Vol.51 (3), p.502-511
Main Author: Laakso, M
Other Authors: Zilinskaite, J , Hansen, T , Boesgaard, T. Welløv , Vänttinen, M , Stančáková, A , Jansson, P.-A , Pellmé, F , Holst, J. J , Kuulasmaa, T , Hribal, M. L , Sesti, G , Stefan, N , Fritsche, A , Häring, H , Pedersen, O , Smith, U
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin/Heidelberg: Springer-Verlag
ID: ISSN: 0012-186X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_prod_swepub_kib_ki_se_116554536
title: Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study
format: Article
creator:
  • Laakso, M
  • Zilinskaite, J
  • Hansen, T
  • Boesgaard, T. Welløv
  • Vänttinen, M
  • Stančáková, A
  • Jansson, P.-A
  • Pellmé, F
  • Holst, J. J
  • Kuulasmaa, T
  • Hribal, M. L
  • Sesti, G
  • Stefan, N
  • Fritsche, A
  • Häring, H
  • Pedersen, O
  • Smith, U
subjects:
  • Adult
  • Article
  • Biological and medical sciences
  • Blood Glucose - metabolism
  • Dextrose
  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2 - blood
  • Diabetes Mellitus, Type 2 - genetics
  • Diabetes. Impaired glucose tolerance
  • Endocrine pancreas. Apud cells (diseases)
  • Endocrinology and Diabetes
  • Endocrinopathies
  • Endokrinologi och diabetes
  • Etiopathogenesis. Screening. Investigations. Target tissue resistance
  • Family
  • Fasting
  • Female
  • Gastric Inhibitory Polypeptide - blood
  • Glucagon
  • Glucagon-Like Peptide 1 - blood
  • Glucose
  • Glucose Intolerance - blood
  • Glucose Intolerance - genetics
  • Glucose Intolerance/blood/genetics
  • Glucose metabolism
  • Glucose Tolerance Test
  • Glucose tolerance tests
  • Human Physiology
  • Humans
  • Hyperglycemia
  • Insulin
  • Insulin - blood
  • Insulin - metabolism
  • Insulin resistance
  • Insulin Secretion
  • Insulin/blood/secretion
  • Internal Medicine
  • Male
  • Medical sciences
  • Medicin och hälsovetenskap
  • Medicine
  • Medicine & Public Health
  • Metabolic Diseases
  • Middle Aged
  • Polypeptides
  • Reference Values
  • Type 2/blood/genetics
ispartof: Diabetologia, 2007-12-14, Vol.51 (3), p.502-511
description: Aims/hypothesis We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. Methods Non-diabetic offspring ( n  = 874; mean age 40 ± 10.4 years; BMI 26.6 ± 4.9 kg/m 2 ) of type 2 diabetic patients from five different European Centres (Denmark, Finland, Germany, Italy and Sweden) were examined with regard to insulin sensitivity (euglycaemic clamps), insulin release (IVGTT) and glucose tolerance (OGTT). The levels of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) were measured during the OGTT in 278 individuals. Results Normal glucose tolerance was found in 634 participants, while 110 had isolated IFG, 86 had isolated IGT and 44 had both IFG and IGT, i.e. about 28% had a form of reduced glucose tolerance. Participants with isolated IFG had lower glucose-corrected first-phase (0–10 min) and higher second-phase insulin release (10–60 min) during the IVGTT, while insulin sensitivity was reduced in all groups with abnormal glucose tolerance. Similarly, GLP-1 but not GIP levels were reduced in individuals with abnormal glucose tolerance. Conclusions/interpretation The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanism leading to postglucose load hyperglycaemia is insulin resistance. Reduced GLP-1 levels were seen in all groups with abnormal glucose tolerance and were unrelated to the insulin release pattern during an IVGTT.
language: eng
source:
identifier: ISSN: 0012-186X
fulltext: no_fulltext
issn:
  • 0012-186X
  • 1432-0428
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5241773
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_prod_swepub_kib_ki_se_116554536
sourceformatXML
sourcesystemPC
galeidA328367767
sourcerecordidA328367767
originalsourceidFETCH-LOGICAL-1667t-3147ad00b2a0711a680fdfb883c83191e2ee8fad6a732c168204033e561416800
addsrcrecordideNqNUsFu1DAQjRCILoUP4IIiKjg17dhObO-xqpZSqYILlbhZ3mSSuvXaS-y06hfxmzjd0IWKViiyMn5-7409M1n2lsABARCHAYDQqkhhAXI-L-izbEZKRgsoqXyezcbjgkj-fSd7FcIlALCq5C-zHSJBAgE-y36eujBY4_KALphork283c_NBPZoUQfMtWvyzg617rwrrLnCfI3raBosSG7xGm1IkoT1wbuQ35h4kZvVWpsem7zVIRrX3en9xuvQ99vz33j0Fnvtahyt4gXmi_OTxZcFzUMcmtvX2YtW24Bvpv9udv5p8e34c3H29eT0-OisIJyLWDBSCt0ALKkGQYjmEtqmXUrJasnInCBFlK1uuBaM1oRLCiUwhhUnZdoB7GbzjW-4wfWwVOverHR_q7w2KfaNmvArMy4VUBHCq6qsGE_a_Ue13bBWCeqGUSIpu6N_3NCT748BQ1QrE2q0Vjv0Q1ACKOeElYn4_gHx0g-9S2VQlDBZ8krQRNrbkDptURnX-tjrenRUR4xKxoXg4kkWESUpORNjwoN_sNLX4MrU3mFrEv6X7X8J_sxANoK69yH02N4Xi4AaZ1ttZluN4Tjbanzhu6kMw3KFzVYxDXMifJgIOtTatuM0mXDPowBcVnc9Fg-S1ybqaLxLtzb2ySvQqcPJ1HXYbzvxuOgXx4ohzQ
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid213846572
display
typearticle
titleInsulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study
creatorLaakso, M ; Zilinskaite, J ; Hansen, T ; Boesgaard, T. Welløv ; Vänttinen, M ; Stančáková, A ; Jansson, P.-A ; Pellmé, F ; Holst, J. J ; Kuulasmaa, T ; Hribal, M. L ; Sesti, G ; Stefan, N ; Fritsche, A ; Häring, H ; Pedersen, O ; Smith, U
creatorcontribLaakso, M ; Zilinskaite, J ; Hansen, T ; Boesgaard, T. Welløv ; Vänttinen, M ; Stančáková, A ; Jansson, P.-A ; Pellmé, F ; Holst, J. J ; Kuulasmaa, T ; Hribal, M. L ; Sesti, G ; Stefan, N ; Fritsche, A ; Häring, H ; Pedersen, O ; Smith, U ; EUGENE2 Consortium ; for the EUGENE2 Consortium ; Sahlgrenska akademin ; Institute of Medicine, Department of Molecular and Clinical Medicine ; Institutionen för medicin, avdelningen för molekylär och klinisk medicin ; Göteborgs universitet ; Gothenburg University ; Sahlgrenska Academy
descriptionAims/hypothesis We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. Methods Non-diabetic offspring ( n  = 874; mean age 40 ± 10.4 years; BMI 26.6 ± 4.9 kg/m 2 ) of type 2 diabetic patients from five different European Centres (Denmark, Finland, Germany, Italy and Sweden) were examined with regard to insulin sensitivity (euglycaemic clamps), insulin release (IVGTT) and glucose tolerance (OGTT). The levels of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) were measured during the OGTT in 278 individuals. Results Normal glucose tolerance was found in 634 participants, while 110 had isolated IFG, 86 had isolated IGT and 44 had both IFG and IGT, i.e. about 28% had a form of reduced glucose tolerance. Participants with isolated IFG had lower glucose-corrected first-phase (0–10 min) and higher second-phase insulin release (10–60 min) during the IVGTT, while insulin sensitivity was reduced in all groups with abnormal glucose tolerance. Similarly, GLP-1 but not GIP levels were reduced in individuals with abnormal glucose tolerance. Conclusions/interpretation The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanism leading to postglucose load hyperglycaemia is insulin resistance. Reduced GLP-1 levels were seen in all groups with abnormal glucose tolerance and were unrelated to the insulin release pattern during an IVGTT.
identifier
0ISSN: 0012-186X
1EISSN: 1432-0428
2DOI: 10.1007/s00125-007-0899-2
3PMID: 18080106
languageeng
publisherBerlin/Heidelberg: Springer-Verlag
subjectAdult ; Article ; Biological and medical sciences ; Blood Glucose - metabolism ; Dextrose ; Diabetes Mellitus ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - genetics ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinology and Diabetes ; Endocrinopathies ; Endokrinologi och diabetes ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Family ; Fasting ; Female ; Gastric Inhibitory Polypeptide - blood ; Glucagon ; Glucagon-Like Peptide 1 - blood ; Glucose ; Glucose Intolerance - blood ; Glucose Intolerance - genetics ; Glucose Intolerance/blood/genetics ; Glucose metabolism ; Glucose Tolerance Test ; Glucose tolerance tests ; Human Physiology ; Humans ; Hyperglycemia ; Insulin ; Insulin - blood ; Insulin - metabolism ; Insulin resistance ; Insulin Secretion ; Insulin/blood/secretion ; Internal Medicine ; Male ; Medical sciences ; Medicin och hälsovetenskap ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Polypeptides ; Reference Values ; Type 2/blood/genetics
ispartofDiabetologia, 2007-12-14, Vol.51 (3), p.502-511
rights
0Springer-Verlag 2007
12008 INIST-CNRS
2COPYRIGHT 2008 Springer
3Springer-Verlag 2008
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1667t-3147ad00b2a0711a680fdfb883c83191e2ee8fad6a732c168204033e561416800
citesFETCH-LOGICAL-1667t-3147ad00b2a0711a680fdfb883c83191e2ee8fad6a732c168204033e561416800
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20068580$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18080106$$D View this record in MEDLINE/PubMed
2$$Uhttps://gup.ub.gu.se/publication/82336$$DView record from Swedish Publication Index
3$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:116554536$$DView record from Swedish Publication Index
search
creatorcontrib
0Laakso, M
1Zilinskaite, J
2Hansen, T
3Boesgaard, T. Welløv
4Vänttinen, M
5Stančáková, A
6Jansson, P.-A
7Pellmé, F
8Holst, J. J
9Kuulasmaa, T
10Hribal, M. L
11Sesti, G
12Stefan, N
13Fritsche, A
14Häring, H
15Pedersen, O
16Smith, U
17EUGENE2 Consortium
18for the EUGENE2 Consortium
19Sahlgrenska akademin
20Institute of Medicine, Department of Molecular and Clinical Medicine
21Institutionen för medicin, avdelningen för molekylär och klinisk medicin
22Göteborgs universitet
23Gothenburg University
24Sahlgrenska Academy
title
0Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study
1Diabetologia
addtitle
0Diabetologia
1Diabetologia
descriptionAims/hypothesis We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. Methods Non-diabetic offspring ( n  = 874; mean age 40 ± 10.4 years; BMI 26.6 ± 4.9 kg/m 2 ) of type 2 diabetic patients from five different European Centres (Denmark, Finland, Germany, Italy and Sweden) were examined with regard to insulin sensitivity (euglycaemic clamps), insulin release (IVGTT) and glucose tolerance (OGTT). The levels of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) were measured during the OGTT in 278 individuals. Results Normal glucose tolerance was found in 634 participants, while 110 had isolated IFG, 86 had isolated IGT and 44 had both IFG and IGT, i.e. about 28% had a form of reduced glucose tolerance. Participants with isolated IFG had lower glucose-corrected first-phase (0–10 min) and higher second-phase insulin release (10–60 min) during the IVGTT, while insulin sensitivity was reduced in all groups with abnormal glucose tolerance. Similarly, GLP-1 but not GIP levels were reduced in individuals with abnormal glucose tolerance. Conclusions/interpretation The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanism leading to postglucose load hyperglycaemia is insulin resistance. Reduced GLP-1 levels were seen in all groups with abnormal glucose tolerance and were unrelated to the insulin release pattern during an IVGTT.
subject
0Adult
1Article
2Biological and medical sciences
3Blood Glucose - metabolism
4Dextrose
5Diabetes Mellitus
6Diabetes Mellitus, Type 2 - blood
7Diabetes Mellitus, Type 2 - genetics
8Diabetes. Impaired glucose tolerance
9Endocrine pancreas. Apud cells (diseases)
10Endocrinology and Diabetes
11Endocrinopathies
12Endokrinologi och diabetes
13Etiopathogenesis. Screening. Investigations. Target tissue resistance
14Family
15Fasting
16Female
17Gastric Inhibitory Polypeptide - blood
18Glucagon
19Glucagon-Like Peptide 1 - blood
20Glucose
21Glucose Intolerance - blood
22Glucose Intolerance - genetics
23Glucose Intolerance/blood/genetics
24Glucose metabolism
25Glucose Tolerance Test
26Glucose tolerance tests
27Human Physiology
28Humans
29Hyperglycemia
30Insulin
31Insulin - blood
32Insulin - metabolism
33Insulin resistance
34Insulin Secretion
35Insulin/blood/secretion
36Internal Medicine
37Male
38Medical sciences
39Medicin och hälsovetenskap
40Medicine
41Medicine & Public Health
42Metabolic Diseases
43Middle Aged
44Polypeptides
45Reference Values
46Type 2/blood/genetics
issn
00012-186X
11432-0428
fulltextfalse
rsrctypearticle
creationdate2007
recordtypearticle
recordideNqNUsFu1DAQjRCILoUP4IIiKjg17dhObO-xqpZSqYILlbhZ3mSSuvXaS-y06hfxmzjd0IWKViiyMn5-7409M1n2lsABARCHAYDQqkhhAXI-L-izbEZKRgsoqXyezcbjgkj-fSd7FcIlALCq5C-zHSJBAgE-y36eujBY4_KALphork283c_NBPZoUQfMtWvyzg617rwrrLnCfI3raBosSG7xGm1IkoT1wbuQ35h4kZvVWpsem7zVIRrX3en9xuvQ99vz33j0Fnvtahyt4gXmi_OTxZcFzUMcmtvX2YtW24Bvpv9udv5p8e34c3H29eT0-OisIJyLWDBSCt0ALKkGQYjmEtqmXUrJasnInCBFlK1uuBaM1oRLCiUwhhUnZdoB7GbzjW-4wfWwVOverHR_q7w2KfaNmvArMy4VUBHCq6qsGE_a_Ue13bBWCeqGUSIpu6N_3NCT748BQ1QrE2q0Vjv0Q1ACKOeElYn4_gHx0g-9S2VQlDBZ8krQRNrbkDptURnX-tjrenRUR4xKxoXg4kkWESUpORNjwoN_sNLX4MrU3mFrEv6X7X8J_sxANoK69yH02N4Xi4AaZ1ttZluN4Tjbanzhu6kMw3KFzVYxDXMifJgIOtTatuM0mXDPowBcVnc9Fg-S1ybqaLxLtzb2ySvQqcPJ1HXYbzvxuOgXx4ohzQ
startdate20071214
enddate20071214
creator
0Laakso, M
1Zilinskaite, J
2Hansen, T
3Boesgaard, T. Welløv
4Vänttinen, M
5Stančáková, A
6Jansson, P.-A
7Pellmé, F
8Holst, J. J
9Kuulasmaa, T
10Hribal, M. L
11Sesti, G
12Stefan, N
13Fritsche, A
14Häring, H
15Pedersen, O
16Smith, U
general
0Springer-Verlag
1Springer
2Springer Nature B.V
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
103V.
117T5
127X7
137XB
1488E
158AO
168C1
178FI
188FJ
198FK
20ABUWG
21BENPR
22FYUFA
23GHDGH
24H94
25K9.
26M0S
27M1P
28PQEST
29PQQKQ
30PQUKI
31PRINS
327X8
33ADTPV
34AOWAS
35D8T
sort
creationdate20071214
titleInsulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study
authorLaakso, M ; Zilinskaite, J ; Hansen, T ; Boesgaard, T. Welløv ; Vänttinen, M ; Stančáková, A ; Jansson, P.-A ; Pellmé, F ; Holst, J. J ; Kuulasmaa, T ; Hribal, M. L ; Sesti, G ; Stefan, N ; Fritsche, A ; Häring, H ; Pedersen, O ; Smith, U
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1667t-3147ad00b2a0711a680fdfb883c83191e2ee8fad6a732c168204033e561416800
rsrctypearticles
prefilterarticles
languageeng
creationdate2007
topic
0Adult
1Article
2Biological and medical sciences
3Blood Glucose - metabolism
4Dextrose
5Diabetes Mellitus
6Diabetes Mellitus, Type 2 - blood
7Diabetes Mellitus, Type 2 - genetics
8Diabetes. Impaired glucose tolerance
9Endocrine pancreas. Apud cells (diseases)
10Endocrinology and Diabetes
11Endocrinopathies
12Endokrinologi och diabetes
13Etiopathogenesis. Screening. Investigations. Target tissue resistance
14Family
15Fasting
16Female
17Gastric Inhibitory Polypeptide - blood
18Glucagon
19Glucagon-Like Peptide 1 - blood
20Glucose
21Glucose Intolerance - blood
22Glucose Intolerance - genetics
23Glucose Intolerance/blood/genetics
24Glucose metabolism
25Glucose Tolerance Test
26Glucose tolerance tests
27Human Physiology
28Humans
29Hyperglycemia
30Insulin
31Insulin - blood
32Insulin - metabolism
33Insulin resistance
34Insulin Secretion
35Insulin/blood/secretion
36Internal Medicine
37Male
38Medical sciences
39Medicin och hälsovetenskap
40Medicine
41Medicine & Public Health
42Metabolic Diseases
43Middle Aged
44Polypeptides
45Reference Values
46Type 2/blood/genetics
toplevelpeer_reviewed
creatorcontrib
0Laakso, M
1Zilinskaite, J
2Hansen, T
3Boesgaard, T. Welløv
4Vänttinen, M
5Stančáková, A
6Jansson, P.-A
7Pellmé, F
8Holst, J. J
9Kuulasmaa, T
10Hribal, M. L
11Sesti, G
12Stefan, N
13Fritsche, A
14Häring, H
15Pedersen, O
16Smith, U
17EUGENE2 Consortium
18for the EUGENE2 Consortium
19Sahlgrenska akademin
20Institute of Medicine, Department of Molecular and Clinical Medicine
21Institutionen för medicin, avdelningen för molekylär och klinisk medicin
22Göteborgs universitet
23Gothenburg University
24Sahlgrenska Academy
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Immunology Abstracts
11Health & Medical Collection
12ProQuest Central (purchase pre-March 2016)
13Medical Database (Alumni Edition)
14ProQuest Pharma Collection
15Public Health Database
16Hospital Premium Collection
17Hospital Premium Collection (Alumni Edition)
18ProQuest Central (Alumni) (purchase pre-March 2016)
19ProQuest Central (Alumni Edition)
20ProQuest Central
21Health Research Premium Collection
22Health Research Premium Collection (Alumni)
23AIDS and Cancer Research Abstracts
24ProQuest Health & Medical Complete (Alumni)
25Health & Medical Collection (Alumni Edition)
26Medical Database
27ProQuest One Academic Eastern Edition
28ProQuest One Academic
29ProQuest One Academic UKI Edition
30ProQuest Central China
31MEDLINE - Academic
32SwePub
33SwePub Articles
34SWEPUB Freely available online
jtitleDiabetologia
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Laakso, M
1Zilinskaite, J
2Hansen, T
3Boesgaard, T. Welløv
4Vänttinen, M
5Stančáková, A
6Jansson, P.-A
7Pellmé, F
8Holst, J. J
9Kuulasmaa, T
10Hribal, M. L
11Sesti, G
12Stefan, N
13Fritsche, A
14Häring, H
15Pedersen, O
16Smith, U
aucorp
0EUGENE2 Consortium
1for the EUGENE2 Consortium
2Sahlgrenska akademin
3Institute of Medicine, Department of Molecular and Clinical Medicine
4Institutionen för medicin, avdelningen för molekylär och klinisk medicin
5Göteborgs universitet
6Gothenburg University
7Sahlgrenska Academy
formatjournal
genrearticle
ristypeJOUR
atitleInsulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study
jtitleDiabetologia
stitleDiabetologia
addtitleDiabetologia
date2007-12-14
risdate2007
volume51
issue3
spage502
epage511
pages502-511
issn0012-186X
eissn1432-0428
abstractAims/hypothesis We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. Methods Non-diabetic offspring ( n  = 874; mean age 40 ± 10.4 years; BMI 26.6 ± 4.9 kg/m 2 ) of type 2 diabetic patients from five different European Centres (Denmark, Finland, Germany, Italy and Sweden) were examined with regard to insulin sensitivity (euglycaemic clamps), insulin release (IVGTT) and glucose tolerance (OGTT). The levels of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) were measured during the OGTT in 278 individuals. Results Normal glucose tolerance was found in 634 participants, while 110 had isolated IFG, 86 had isolated IGT and 44 had both IFG and IGT, i.e. about 28% had a form of reduced glucose tolerance. Participants with isolated IFG had lower glucose-corrected first-phase (0–10 min) and higher second-phase insulin release (10–60 min) during the IVGTT, while insulin sensitivity was reduced in all groups with abnormal glucose tolerance. Similarly, GLP-1 but not GIP levels were reduced in individuals with abnormal glucose tolerance. Conclusions/interpretation The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanism leading to postglucose load hyperglycaemia is insulin resistance. Reduced GLP-1 levels were seen in all groups with abnormal glucose tolerance and were unrelated to the insulin release pattern during an IVGTT.
copBerlin/Heidelberg
pubSpringer-Verlag
pmid18080106
doi10.1007/s00125-007-0899-2
oafree_for_read